 Background insulin glargine dose decreased over time from a geometric mean baseline of 46 IU with tirzepatide (geometric mean daily insulin glargine dose at week 52: pooled tirzepatide, 13 IU [0.15 IU/kg]; 5-mg tirzepatide, 20 IU [0.24 IU/kg]; 10-mg tirzepatide, 12 IU [0.15 IU/kg]; 15-mg tirz- epatide, 8 IU [0.10 IU/kg]), with 8% to 19% of tirzepatide- treated participants completely discontinuing insulin glargine therapy by week 52 (eFigure 9 inSupplement 2). At week 52, geometric mean daily dose of insulin lispro was Figure 2. Effect of Tirzepatide vs Insulin Lispro on Hemoglobin A1c (HbA1c) and Body Weight 14 8 9 10 11 12 13 7 6 5 4 3 HbA1c, % Time since randomization, wk Hemoglobin A1c (HbA1c)A 5 mg Tirzepatide   10 mg Insulin lispro 15 mg Pooled 0 708 716 No. of participants Pooled tirzepatide Insulin lispro 4 673 700 8 678 697 12 671 696 16 666 695 20 653 695 24 655 696 40 640 678 52 629 689 30 –30 –40 –20 –10 0 10 20 Change from baseline in body weight, kg Time since randomization, wk Body weightB 0 708 716 No. of participants Pooled tirzepatide Insulin lispro 4 682 708 8 683 705 12 675 704 16 671 704 20 659 698 24 658 697 32 648 693 40 645 690 52 632 689 Overall mean baseline body weight = 91 kg Insulin lisproPooled tirzepatide   Overall mean baseline HbA1c = 8.80% A, Lines show the values for least-squares mean HbA1c levels over time derived from a mixed-model repeated-measures analysis (efficacy estimand). To convert HbA1c values to mmol/mol, use the equation 10.93 × HbA1c) − 23.50.